Symbol | Exchange | Currency |
|---|
Oxford Biomedica shares are on the rise after the company reported a strong financial performance in 1H21.Revenue increased 139% Y/Y to £81.3M, driven exceptional growth (223%...
Oxford Biomedica plc (OXBDF): 1H GAAP EPS of 21.36p.Revenue of £81.3M (+139.1% Y/Y)Press Release
Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million...
Determined to make the New Year better than the last, the European indices opened the first trading day of 2021 with much fanfare this Monday. Despite the rapid increase in daily...
Watch our week ahead video preview, read our pick of the top stories to look out for this week (14-18 September), and view our key company earnings schedule.Our UK chief market...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Neutral | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Neutral | Strong Buy |
| Summary | Strong Buy | Buy | Strong Sell | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 107.80 | 107.80 | 107.80 | +0.50 | +0.48% | 232.25K | London | |||
| 6.05 | 11.11 | 6.30 | 0.00 | 0.00% | 0.00 | London | |||
| 203.20 | 207.90 | 202.70 | -4.00 | -1.93% | 25.09M | London | |||
| 45.50 | 46.17 | 45.25 | -0.34 | -0.74% | 153.21M | London | |||
| 256.00 | 285.00 | 252.00 | -22.00 | -7.91% | 159.66K | London | |||
| 272.20 | 284.20 | 271.80 | -4.00 | -1.45% | 1.42M | London | |||
| 3,271.00 | 3,406.00 | 3,265.00 | -128.0 | -3.77% | 264.12K | London | |||
| 158.70 | 165.80 | 157.85 | -6.85 | -4.14% | 26.79M | London | |||
| 6.50 | 6.50 | 6.50 | +0.050 | +0.78% | 403.91K | London | |||
| 2,700.50 | 2,706.00 | 2,661.50 | +27.0 | +1.01% | 3.66M | London | |||
| 114.98 | 116.32 | 114.88 | -0.90 | -0.78% | 49.03M | London | |||
| 260.10 | 269.20 | 258.20 | -5.40 | -2.03% | 5.92M | London | |||
| 813.50 | 880.50 | 784.50 | -50.50 | -5.84% | 2.34M | London | |||
| 221.10 | 223.50 | 218.40 | +0.40 | +0.18% | 15.95M | London | |||
| 14.20 | 20.70 | 12.50 | 0.00 | 0.00% | 0.00 | London |
Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.